Prediction model of delayed graft function based on clinical characteristics combined with serum IL-2 levels

Shitao Zhao†, Yuan Liu†, Chen Zhou†, Zide Chen, Zeyu Cai, JiaLiang Han, Jiansheng Xiao* and Qi Xiao*

Abstract
Background: Kidney transplantation is an effective treatment for end-stage renal disease (ESRD). Delayed graft function (DGF) is a common complication after kidney transplantation and exerts substantial effects on graft function and long-term graft survival. Therefore, the construction of an effective model to predict the occurrence of DGF is particularly important.

Methods: Seventy-one patients receiving their first kidney transplant at the First Affiliated Hospital of Nanchang University from October 2020 to October 2021 were enrolled in the discovery cohort. Based on clinical characteristics and serum markers, a logistic regression model was used to simulate the risk of DGF in the discovery cohort. The DGF prediction model was named the prediction system and was composed of risk factors related to DGF. Thirty-two patients receiving a kidney transplant at the First Affiliated Hospital of Nanchang University from October 2021 to February 2022 were enrolled in the validation cohort. The validation cohort was used to verify the accuracy and reliability of the prediction model.

Results: Cold ischemia time (CIT), donor history of diabetes mellitus, donor interleukin-2 (IL-2) level and donor terminal creatinine level constitute the prediction system. In the validation test, the area under the receiver operating characteristic curve (AUC) was 0.867 for the prediction system, and good calibration of the model was confirmed in the validation cohort.

Conclusions: This study constructed a reliable and highly accurate prediction model that provides a practical tool for predicting DGF. Additionally, IL-2 participates in the kidney injury process and may be a potential marker of kidney injury.

Keywords: Kidney transplantation, Delayed graft function, Interleukin-2, Cold ischemia time, Diabetes, Creatinine

Introduction
Kidney transplantation is an effective treatment for end-stage renal disease. However, the demand and supply disparity among patients waiting for kidney transplants and the availability of donor organs is widening. Expanded criteria donors (ECDs) are increasingly used for transplantation to alleviate the shortage of organs. However, the use of these donors has resulted in a significant increase in postoperative complications (e.g., delayed graft function (DGF)) [1]. Delayed graft function (DGF) is a common complication occurring after kidney transplantation and is associated with postoperative mortality, length of stay and long-term graft survival, among other factors [2, 3]. The definition of DGF is not completely unified at the present stage. The most widely accepted
definition of DGF is a need for dialysis within one week after transplantation [4].

In recent years, transplant centers around the world have begun to build models to predict DGF by collecting preoperative information. Irish et al. [5] first published the DGF prediction model in 2003. Chapal et al. [6] included induction therapy characteristics in the DGF scoring system to improve the predictive power and increased the area under the receiver operating characteristic curve (AUC) to 0.73. However, the DGF prediction model constructed by Zaza et al. [7] only included recipient characteristics without donor characteristics, and the prediction efficiency was lower than that of the previous prediction models (AUC = 0.63). The Kidney Donor Risk Index (KDRI) scoring system [8] has been used for the preoperative prediction of DGF due to its correlation with the risk of DGF. However, the AUC of the KDRI is 0.67. The KDRI plays an important role in donor kidney allocation, which determines whether to accept kidneys from deceased donors, and it does not take into account a number of factors that cause DGF, such as cold ischemia time (CIT), the general condition of the recipient, immune status and other factors.

Clinical characteristics and preoperative kidney injury markers are also important for predicting the occurrence of DGF. Most studies have shown that acute kidney injury (AKI) caused by ischemia–reperfusion injury (IRI) is the main factor contributing to DGF because the production of cytotoxic mediators and activation of innate and adaptive immune responses after reperfusion all cause damage and necrosis of renal tubular cells [9–11]. Interleukins (ILs) play an important role in the immune system and are involved in the process of kidney injury, but they have not been used to assess prognosis after kidney transplantation.

Here, we discuss the involvement of serum markers in renal function impairment, construct a novel, reliable and highly accurate prediction model combine with serum markers, aiming to provide new insights for the DGF prediction after kidney transplantation.

**Materials and methods**

**Study design**

Sample and data collection were approved by the First Affiliated Hospital of Nanchang University ethical committees and were performed according to the Declaration of Helsinki. This study retrospectively collected the clinical characteristics of 39 donors and 77 recipients who underwent transplant surgery at the First Affiliated Hospital of Nanchang University from October 2020 to October 2021. The following classes of renal allograft donor organs or recipients were excluded from the study: (1) they had undergone retransplantation or were transplanted with organs other than the kidneys; (2) had a positive crossmatch or positive panel-reactive antibody (PRA > 10%); (3) had abnormal hepatic function; (4) patients who had autoimmune disease or received immunosuppressive therapy before the transplant procedure; (5) living related donor; (6) patients who displayed less than seven days of patient-and-graft survival (the diagnosis of DGF takes 1 week); and (7) patients who underwent a double-kidney transplant. Five recipients were excluded due to retransplantation, one recipient was excluded due to double kidney transplants. Finally, 71 recipients were included in the discovery cohort.

In addition, we collected information on 17 donors and 32 recipients who underwent transplant surgery at the First Affiliated Hospital of Nanchang University from October 2021 to February 2022 as a validation cohort to validate the predictive value of our model (Fig. 1).

**Sample collection and the experimental procedure**

**1 Sample collection:**

(1) Donor blood sample collection: When donor death was declared, donor peripheral blood samples (10 ml) were collected into a tube containing EDTA.

(2) Recipient blood sample collection: Recipient peripheral blood samples were collected into tubes (10 ml) containing EDTA before the induction of immunosuppression.

**2 Flow cytometry experimental procedure:** The frequency of Tregs was measured using flow cytometry. The main experimental equipment includes: CTYOMICS FC 500 flow cytometer, lysis solution (Beckman Coulter, Inc., CA, USA); CD4-FITC, CD25-PC5, and CD127-PE antibodies (BD Pharmingen, San Diego, CA, USA); and phosphate-buffered saline (Bwsm, Inc., Beijing, China).

**3 ELISA experimental procedure:** Plasma levels of interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-6 (IL-6), interleukin-10 (IL-10), cytotoxic T-lymphocyte-associated protein-4/cluster of differentiation 152 (CTLA-4/CD152), interleukin-35 (IL-35), and high mobility group Box 1 protein (HMGB1) were measured in the groups using commercially available enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer's instructions. The main experimental equipment included IL-2, IL-4, IL-6, IL-10, CTLA-4/CD152, IL-35, and HMGB1 ELISA kits (ML Bio Inc., Shanghai, China).

**Study end points**

DGF was defined as a need for dialysis in the first week after transplantation. Dialysis with heart failure was
excluded. Patients who displayed less than seven days of patient-and-graft survival were excluded.

**Statistical analyses**

Continuous variables are presented as the means ± standard deviations (SD) or medians (interquartile ranges [IQRs]), and categorical data are presented as percentages. Differences in continuous variables were analyzed using Student’s t tests or the Mann–Whitney U test. Categorical data were evaluated using the chi-square or Fisher exact test, as appropriate.

(1) **Construction of the prediction model:** This analysis was performed based on the discovery cohort (n=71) using a multivariate logistic regression analysis. The
(2) Validation of the prediction model: Model efficacy was verified by analyzing the data from the discovery cohort (internal validation) and the validation cohort (external validation). For internal validation: The number of independent predictors of DGF were identified if their P value was less than 0.05. The regression coefficients of the predictive variables in the logistic regression model were used to establish the nomogram to predict DGF. The regression coefficients of the predictive variables in the logistic regression model were used to establish the nomogram to predict DGF.

Model efficacy was verified by analyzing the data from the discovery cohort (internal validation) and the validation cohort (external validation). For internal validation: The predictive ability of the prediction model was assessed using a c-statistic of the receiver operating characteristic curve (ROC), and the 95% Confidence Interval (CI) of the areas under the ROC curves (AUCs) were non-parametrically obtained by bootstrap resampling (1000 bootstraps). The model prediction threshold was compared by performing decision curve analysis (DCA). By drawing a calibration diagram (1000 bootstraps), the performance characteristics of the model are shown graphically. We calculated the Brier score and R-squared values of the model. For external validation: This analysis was repeated using data from the validation cohort. The validation cohort was divided into ten groups, and the DGF prediction model calibration was evaluated using the Hosmer-Lemeshow statistic.

The statistical analyses were performed using SPSS software version 24.0 (SPSS Inc., Chicago, IL, USA), MedCalc statistical software version 19.6 (MedCalc Software Ltd., Ostend, Belgium) and R version 4.12 (R Project for Statistical Computing, Vienna, Austria).

### Table 1 Recipient and donor characteristics at time of transplantation in the discovery cohort (n = 71) and validation cohort (n = 32)

| Variable                      | Discovery cohort (n = 71) | Validation cohort (n = 32) | P    |
|-------------------------------|--------------------------|---------------------------|------|
| **Recipient characteristics** |                          |                           |      |
| Age, yr                       | 37.97 ± 11.49            | 37.28 ± 13.50             | 0.790|
| Gender                        |                          |                           | 0.333|
| Male                          | 47 (66.2%)               | 18 (56.3%)                |      |
| Female                        | 24 (33.8%)               | 14 (43.8%)                |      |
| BMI, kg/m²                    | 21.44 (18.67–24.36)      | 20.10 (18.11–23.53)       | 0.259|
| Time on dialysis, m           | 24 (15–60)               | 24 (12–59.25)             | 0.338|
| Dialysis, HD                  | 51 (71.8%)               | 19 (59.4%)                | 0.403|
| Immunosuppression regimen     |                          |                           | 0.267|
| ATG, Tac, MMF, steroid        | 15 (21.1%)               | 10 (31.3%)                |      |
| Basiliximab, Tac, MMF, steroid | 61 (85.9%)              | 24 (75.0%)                |      |
| Pre-Tx Creatinine, mg/dL      | 12.05 ± 3.68             | 11.03 ± 3.43              | 0.189|
| history of hypertension       | 61 (85.9%)               | 22 (78.6%)                | 0.177|
| history of diabetes mellitus  | 3 (4.2%)                 | 0 (0%)                    | 0.238|
| **Donor characteristics**     |                          |                           |      |
| Age, (yr)                     | 44 (17–48)               | 29.5 (15–51.25)           | 0.471|
| Gender                        |                          |                           | 0.545|
| Male                          | 57 (80.3%)               | 24 (75.0%)                |      |
| Female                        | 14 (19.7%)               | 8 (25.0%)                 |      |
| BMI, kg/m²                    | 22.86 (18.81–24.22)      | 23.75 (18.11–24.80)       | 0.526|
| Terminal Creatinine, mg/dL    | 0.88 (0.67–1.52)         | 0.72 (0.59–1.46)          | 0.279|
| The donor type                |                          |                           | 0.155|
| DCD                           | 13 (18.3%)               | 4 (12.5%)                 |      |
| DBD                           | 52 (73.2%)               | 28 (87.5%)                |      |
| DBCD                          | 6 (8.5%)                 | 0 (0%)                    |      |
| Donor history of hypertension | 32 (45.1%)               | 10 (31.3%)                | 0.187|
| Donor history of diabetes mellitus | 16 (22.5%)   | 3 (9.4%)                  | 0.111|
| **Transplant characteristics**|                          |                           |      |
| CIT, h                        | 9 (7–11)                 | 9 (7–9.375)               | 0.309|
| HLA mismatches                | 5 (4–5)                  | 4 (4–5)                   | 0.371|

**Continuous variables were expressed as the mean ± SD or IQR, categorical data were expressed as n%**

ATG Anti-thymocyte globulin, Tac Tacrolimus, MMF Mycophenolate Mofetil, Pre-Tx Pre-transplant, HD Hemodialysis, CIT Cold ischemia time, HLA Human leukocyte antigen, DCD Donation after cardiac death, DBD Donation after brain death, DBCD Donation after brain death plus cardiac death, BMI Body mass index, NA Not available
Results
Donor, recipient, and transplant characteristics
A total of 103 patients were enrolled in the discovery cohort (n = 71) and validation cohort (n = 32). Table 1 shows no significant differences in the demographic and clinical characteristics between the discovery cohort and validation cohort. Table 2 lists the differences in recipient and donor baseline characteristics between the DGF group and the immediate graft function (IGF) group. In the discovery cohort, the donor terminal creatinine level in the IGF group (0.80 (0.67–1.08)) was significantly lower than that in the DGF group (1.52 (0.87–4.24)) (P = 0.001). The proportion of patients with a donor history of hypertension in the IGF group (17 (35.4%)) was lower than that in the DGF group (15 (65.2%)) (P = 0.018). The proportion of donors with a history of diabetes mellitus in the IGF group (6 (12.5%)) was also lower than that in the DGF group (10 (43.5%)) (P = 0.003). The CIT in the IGF group (8.36 ± 2.27) was significantly shorter than that in the DGF group (10.61 ± 2.82) (P = 0.001). In contrast, the proportion of a recipient history of hypertension in the IGF group (44 (91.7%)) was higher than that in the DGF group (17 (73.9%)) (P = 0.044). Table 3 lists the differences in recipient and donor serum markers and Treg levels between the DGF group and the IGF group. In the discovery cohort, the donor IL-2 level in the IGF group (74.23 ± 23.96) was lower than that in the DGF group (96.42 ± 26.46) (P = 0.001). No significant differences in the levels of other serum markers or Tregs were observed between the groups.

Table 2 The recipient and donor characteristics of DGF and IGF in the Discovery cohort and the validation cohort

| Variable                      | Discovery cohort (n = 71) | Validation cohort (n = 32) | p           |
|-------------------------------|--------------------------|---------------------------|-------------|
|                               | DGF (n = 23)             | IGF (n = 48)              | DGF (n = 12) | IGF (n = 20) | P     |
| **Recipient characteristics** |                          |                           |             |
| Age, yr                       | 39.26 ± 10.76            | 37.35 ± 11.83             | 0.517       | 36.67 ± 13.30 | 37.65 ± 13.95 | 0.846 |
| Gender                        |                          |                           | 0.904       | 0.854       |
| Male                          | 15 (65.2%)               | 32 (66.7%)                |             |             |
| Female                        | 8 (34.8%)                | 16 (33.3%)                |             |             |
| BMI, kg/m²                    | 22.53 ± 5.01             | 21.49 ± 3.58              | 0.317       | 20.38 ± 4.23 | 20.98 ± 3.20 | 0.654 |
| Time on dialysis, m           | 36 (24–84)               | 24 (12.5–49.5)            | 0.110       | 24 (13.75–29.75) | 22 (12–60) | 0.876 |
| Dialysis, HD                  | 16 (69.6%)               | 35 (72.9%)                | 0.506       | 9 (75.0%)   | 10 (50%)   | 0.289 |
| **Immunosuppression regimen** |                          |                           |             |
| ATG, Tac, MMF, steroid        | 10 (20.8%)               | 5 (10.8%)                 | 0.988       | 11.19 ± 3.51 | 10.93 ± 3.48 | 0.881 |
| Basiliximab, Tac, MMF, steroid| 38 (79.2%)               | 40 (90.2%)                |             |             |
| History of hypertension       | 17 (73.9%)               | 44 (91.7%)                | 0.044       | 8 (66.7%)   | 16 (80.0%) | 0.399 |
| History of diabetes mellitus  | 0 (0%)                   | 3 (6.3%)                  | 0.221       | 0 (0%)      | 0 (0%)     | NA     |
| **Donor characteristics**     |                          |                           |             |
| Age, yr                       | 43 (35–47)               | 46 (17–49.75)             | 0.631       | 38.50 ± 18.76 | 27.70 ± 15.87 | 0.092 |
| Gender                        |                          |                           | 0.106       | 0.092       |
| Male                          | 21 (91.3%)               | 36 (75.0%)                | 0.671       | 24.62 (18.53–25.48) | 21.35 (18.03–24.46) | 0.226 |
| Female                        | 2 (8.7%)                 | 12 (25.0%)                |             |             |
| BMI, kg/m²                    | 23.39 (18.37–24.46)      | 24.29 (19.42–24.22)       | 0.001       | 0.001       |
| Terminal Creatinine, mg/dL    | 1.52 (0.87–4.24)         | 0.80 (0.67–1.08)          | 0.001       | 0.001       |
| The donor type                |                          |                           | 0.490       | 0.581       |
| DCD                           | 6 (26.1%)                | 7 (14.6%)                 | 2 (16.7%)   | 2 (10%)     |
| DBD                           | 15 (65.2%)               | 37 (77.1%)                | 10 (83.3%)  | 18 (90%)    |
| DBCD                          | 2 (8.7%)                 | 4 (8.3%)                  | NA          | NA          |
| Donor history of hypertension | 15 (65.2%)               | 17 (35.4%)                | 0.018       | 4 (33.3%)   | 2 (10.0%)  | 0.102 |
| Donor history of diabetes mellitus | 10 (43.5%)              | 6 (12.5%)                | 0.003       | 0.003       |
| Transplant characteristics    |                          |                           | 0.637       | 0.637       |
| CIT, h                        | 10.61 ± 2.82             | 8.36 ± 2.27               | 0.001       | 9.5 ± 1.23  | 7.95 ± 1.34 | 0.006 |
| HLA mismatches                | 5 (4–6)                  | 5 (4–5)                   | 0.663       | 4 (4–5.75)  | 4.5 (4–5)  | 0.373 |

Continuous variables were expressed as the mean ± SD or IQR; categorical data were expressed as n%. ATG Anti-thymocyte globulin, Tac Tacrolimus, MMF Mycophenolate Mofetil, Pre-Tx Pre-transplant, HD hemodialysis, CIT Cold ischemia time, HLA Human leukocyte antigen, DCD Donation after cardiac death, DBD Donation after brain death, DBCD Donation after brain death plus cardiac death, BMI Body mass index; NA: Not available.
Univariate and multivariate analyses and construction of the DGF prediction model

Tables 4 and 5 shows the results of univariate analyses and multivariate analyses of the discovery cohort. Univariate logistic analysis showed that donor terminal creatinine levels, donor history of hypertension, donor history of diabetes mellitus, CIT, and donor IL-2 levels were related to postoperative DGF. After adjusting for the effects of the factors listed above in the multivariate logistic regression analysis, CIT, donor history of diabetes mellitus, donor IL-2 levels and donor terminal creatinine levels were considered independent risk factors for DGF. The ROC curve was plotted to evaluate the prediction model and calculate the AUCs (Fig. 2(A)). The AUCs were 0.753 for donor terminal creatinine levels, 0.655 for a donor history of diabetes mellitus, 0.706 for the CIT, and 0.714 for donor IL-2 levels (Table 6). Finally, these four variables (donor terminal creatinine levels, donor history of diabetes mellitus, CIT, and donor IL-2 levels) constituted the nomogram model (named the prediction system) shown in Fig. 3 to predict DGF after kidney transplantation. The DGF prediction model was calculated using the formula (-9.6319 + 0.368 × CIT + 1.789 × donor history of diabetes mellitus + 0.047 × donor IL-2 level + 0.749 × donor terminal creatinine level).

Evaluating the predictive capacity of the DGF prediction model

We used AUC, decision curve analysis (DCA), and clinical impact curve (CIC) to evaluate the predictive power of the prediction system. The relative efficiencies of the KDRI, delayed graft function score (DGFS) and the prediction system for predicting DGF are shown in Figs. 2 and 4.

Internal validation

In the discovery cohort, the AUCs were 0.894 for the prediction system, 0.764 for the KDRI and 0.720 for the DGFS (Fig. 2C). As shown in Fig. 4A, when the threshold value (P_t) is 0–0.88, the positive probability of DGF is higher with our prediction model, while the threshold value of KDRI (P_t = 0–0.75) and DGFS (P_t = 0–0.77) are narrower. Figure 4C shows that the positive rate predicted by the prediction system is basically the same as the actual positive rate. Figure 5A shows the calibration plot (1000 bootstraps) of the prediction system for the discovery cohort. The bias-corrected solid line represents the prediction system performance, which is close to the ideal. Figure 5C shows the Brier score (0.116) and R-squared value (55.8%) of the prediction system for the discovery cohort (a lower Brier score reflects a more accurate prediction of DGF, and < 0.25 indicates good calibration). All results indicate that the prediction system has good prediction efficiency.

External validation

The validation cohort consisted of 32 kidney transplant recipients for external validation. In the validation cohort, CIT was significantly shorter in the IGF group (7.95 ± 1.34) than in the DGF group (9.5 ± 1.23). The

---

**Table 3** The Donor and recipient serum markers level of DGF and IGF in discovery and validation cohort

| Variables | Discovery cohort (n = 71) | Validation cohort (n = 32) | p | IGF(n = 20) | DGF(n = 12) | p |
|-----------|--------------------------|----------------------------|---|-------------|-------------|---|
| Donor     |                          |                            |   |             |             |   |
| IL-2(pg/mL) | 74.23 ± 23.96           | 96.42 ± 26.46             | 0.001 | 76.22(63.25–95.64) | 97.70(89.56–113.83) | 0.003 |
| IL-4(pg/mL) | 4.55 ± 1.87             | 3.96 ± 2.17               | 0.240 |             |             |   |
| IL-6(pg/mL) | 6.04 ± 1.55             | 5.37 ± 2.12               | 0.138 |             |             |   |
| IL-10(pg/mL) | 67.33 ± 31.53          | 73.59 ± 26.19             | 0.412 |             |             |   |
| CTLA-4;CD152(pg/mL) | 137.91 ± 58.81 | 136 ± 71.36               | 0.909 |             |             |   |
| IL-35(pg/mL) | 9.08(5.22–10.43)       | 9.67(5.79–10.78)          | 0.632 |             |             |   |
| HMGB1(pg/mL) | 5643.15 ± 1493.09     | 5937.63 ± 1968.60         | 0.486 |             |             |   |
| recipient  |                          |                            |   |             |             |   |
| IL-2(pg/mL) | 99.62 ± 23.45           | 94.87 ± 20.93             | 0.411 |             |             |   |
| IL-4(pg/mL) | 5.95 ± 1.79             | 6.26 ± 1.19               | 0.454 |             |             |   |
| IL-6(pg/mL) | 7.65 ± 1.50             | 7.39 ± 1.41               | 0.481 |             |             |   |
| IL-10(pg/mL) | 92.76 ± 21.57          | 89.61 ± 20.24             | 0.559 |             |             |   |
| CTLA-4;CD152(pg/mL) | 214.50 ± 54.42       | 213.83 ± 50.69            | 0.961 |             |             |   |
| IL-35(pg/mL) | 11.01 ± 2.11           | 11.05 ± 2.86              | 0.944 |             |             |   |
| Treg (%)   | 5.10 ± 2.39%            | 5.34 ± 2.53%              | 0.700 |             |             |   |

CTA Cytotoxic T-lymphocyte-associated protein, CD Cluster of differentiation, IL Interleukin, HMGB1 High mobility group box 1 protein, Treg Regulatory T cells
The proportion of donors with a history of diabetes mellitus in the IGF group was lower than that in the DGF group. The donor IL-2 level in the IGF group (76.22 (63.25–95.64)) was lower than that in the DGF group (97.70 (89.56–113.83)). The donor terminal creatinine level was significantly different between the DGF (1.37 (0.92–1.74)) group and IGF (0.67 (0.56–0.8)) group.

Figure 2(B) shows the predictive efficiency of these four variables in the validation cohort. The AUCs were 0.817 for donor terminal creatinine levels, 0.625 for a donor history of diabetes mellitus, 0.769 for the CIT, and 0.819 for donor IL-2 levels (Table 6).

In the validation cohort, the AUC calculated using the prediction system was 0.879, the KDRI was 0.829, and the DGFS was 0.667 (Fig. 2D). In the validation cohort, our prediction model still maintained a high accuracy. As shown in Fig. 4B, our prediction model had a broad threshold, while the KDRI (P = 0.16–0.62) and DGFS (P = 0.3–0.59) thresholds were still low. Our prediction model was better than KDRI in terms of decision-making ability. Figure 5B shows the calibration plot of the prediction system for the validation cohort. The bias-corrected solid line was also close to the ideal. Figure 5D shows the Brier score (0.138) and R-squared value (53.9%) of the prediction system for the validation cohort. The prediction system calibration was evaluated again using the Hosmer–Lemeshow statistic. Figure 6 illustrates the good calibration of the model for the validation cohort; the points in the image are close to the midline. The predicted and observed risks were similar (P = 0.4117, > 0.05 indicates good calibration).

Discussion

DGF is one of the common postoperative complications after kidney transplantation and exerts a substantial effect on graft function and long-term graft survival [2, 3]. The occurrence of DGF was significantly reduced by changing the organ preservation strategy [12]. Therefore, building a reliable and accurate prediction model is important for reducing DGF and improving graft survival.

Table 4 Results of the univariate logistic regression analysis

| Variables                              | Univariate analysis |          |          |
|----------------------------------------|---------------------|----------|----------|
|                                       | OR 95%CI            | P        |          |
| **Recipient characteristics**          |                     |          |          |
| Age, yr                                | 1.015 (0.971–1.061) | 0.511    |          |
| Gender                                 | 0.938 (0.329–2.671) | 0.904    |          |
| BMI, kg/m²                             | 1.065 (0.942–1.203) | 0.313    |          |
| Time on dialysis, m                    | 1.008 (0.995–1.021) | 0.239    |          |
| Dialysis, HD                           | 1.295 (0.534–3.143) | 0.568    |          |
| Immunosuppression regimen              | 1.056 (0.314–3.544) | 0.930    |          |
| Pre-Tx Creatinine, mg/dL               | 1.000 (0.988–1.002) | 0.987    |          |
| history of hypertension                | 0.258 (0.065–1.027) | 0.055    |          |
| history of diabetes mellitus           | NA                  | NA       | NA       |
| **Donor characteristics**              |                     |          |          |
| Age, yr                                | 1.004 (0.976–1.032) | 0.787    |          |
| Gender                                 | 3.500 (0.713–17.176)| 0.123    |          |
| BMI, kg/m²                             | 1.022 (0.890–1.173) | 0.760    |          |
| Terminal Creatinine, mg/dL             | 2.279 (1.395–3.722) | 0.001    |          |
| The donor type                          |                     |          |          |
| DCD                                    | REF                 |          |          |
| DBD                                    | 1.714 (0.228–12.890)| 0.601    |          |
| DBCD                                   | 0.811 (0.134–4.907) | 0.819    |          |
| Donor history of hypertension          | 3.419 (1.206–9.695) | 0.021    |          |
| Donor history of diabetes mellitus     | 5.385 (1.641–17.664)| 0.005    |          |
| **Transplant characteristics**         |                     |          |          |
| CIT, h                                 | 1.438 (1.143–1.809) | 0.002    |          |
| HLA mismatches                         | 1.000 (0.692–1.444) | 0.998    |          |
| **Donor serum markers**                |                     |          |          |
| IL-2(pg/mL)                            | 1.036 (1.013–1.059) | 0.002    |          |
| IL-4(pg/mL)                            | 0.857 (0.663–1.107) | 0.238    |          |
| IL-6(pg/mL)                            | 0.800 (0.595–1.076) | 0.140    |          |
| IL-10(pg/mL)                           | 1.007 (0.990–1.025) | 0.407    |          |
| CTLA-4(pg/mL)                          | 1.000 (0.992–1.008) | 0.908    |          |
| IL-35(pg/mL)                           | 1.002 (0.834–1.205) | 0.982    |          |
| HMGB1(pg/mL)                           | 1.000 (1.000–1.000) | 0.481    |          |
| **Recipient serum markers**            |                     |          |          |
| IL-2(pg/mL)                            | 0.990 (0.968–1.013) | 0.990    |          |
| IL-4(pg/mL)                            | 1.128 (0.826–1.539) | 0.449    |          |
| IL-6(pg/mL)                            | 0.881 (0.623–1.247) | 0.476    |          |
| IL-10(pg/mL)                           | 0.993 (0.969–1.017) | 0.553    |          |
| CTLA-4(pg/mL)                          | 1.000 (0.990–1.009) | 0.960    |          |
| IL-35(pg/mL)                           | 1.008 (0.815–1.245) | 0.943    |          |
| Treg frequency(%)                      | 1.042 (0.848–1.281) | 0.695    |          |

Table 5 Results of the multivariable logistic regression analysis

| Variables                              | Multivariate analysis |          |          |
|----------------------------------------|-----------------------|----------|----------|
|                                       | OR 95%CI              | P        |          |
| **Donor characteristics**              |                       |          |          |
| Terminal Creatinine, mg/dL             | 0.749 (0.676–0.829)   | 0.035    |          |
| Donor history of diabetes mellitus     | 1.789 (1.191–3.048)   | 0.030    |          |
| **Transplant characteristics**         |                       |          |          |
| CIT, h                                 | 0.368 (0.104–1.205)   | 0.026    |          |
| **Donor serum markers**                |                       |          |          |
| IL-2(pg/mL)                            | 0.047 (0.017–0.108)   | 0.003    |          |

ATG Anti-thymocyte globulin, Tac Tacrolimus, MMF Mycophenolate Mofetil, Pre-Tx Pre-transplant, HD Hemodialysis, CIT Cold ischemia time, HLA Human leukocyte antigen, DCD, Donation after cardiac death, DBD Donation after brain death, DBCD Donation after brain death plus cardiac death, BMI Body mass index, CTA cytotoxic T-lymphocyte-associated protein, CD Cluster of differentiation, IL Interleukin, HMGB1 high mobility group box 1 protein, Treg Regulatory T cells, NA Not available
particularly important to address the problems encountered by clinical decision-makers.

In our study, IL-2 was innovatively added to the prediction model. In 1983, IL-2 was discovered as an autocrine growth factor for cultured T cells [13]. IL-2 is involved in the proliferation of T cells and natural killer (NK) cells in the immune system, and may indirectly lead to kidney damage. First, weakening the ability of IL-2 to stimulate T cell proliferation has been shown to reduce ischemia–reperfusion injury (IRI) [14–17]. A study found that in the process of renal ischemia and reperfusion, IL-2 promotes NK cell proliferation, and NK cells directly kill renal tubular epithelial cells (TECs) [18]. Because renal parenchymal cells are mostly TECs, thus excessive apoptosis of TECs may lead to impaired renal function, indicating a potential link between NK cells and kidney injury. In addition to causing kidney damage by inducing the proliferation of immune cells, IL-2 has been reported
to regulate TECs directly, leading to kidney injury. According to a previous study, IL-2 regulates cellular FLICE-inhibitory protein (C-FLIP) in TECs to increase the expression of endogenous caspase-8 in TECs, leading to TEC apoptosis and impaired renal function [19]. IL-2 is also widely used to treat immunodeficiency diseases, but the complications of impaired renal function often occur during treatment [20]. In our study, the level of IL-2 in the donor serum was positively correlated with DGF. This result may be related to the involvement of IL-2 in renal injury.

Creatinine is the product of phosphocreatine decomposition in muscle. It is produced at a fairly constant rate in the body, filtered freely through the glomerular membrane, and discharged almost completely through the kidney [21]. It is a clinically recognized sign of renal function [22]. The use of donor serum creatinine levels to evaluate renal function is a simple, efficient and cost-effective method. However, serum creatinine levels are influenced by other factors, such as diet, age, medications, and other factors, and the effects of other variables must be considered when evaluating kidney functions [23]. In our study, the donor serum creatinine level was included in the prediction model, and other risk factors were combined to improve the accuracy of the prediction. Similarly, the donor serum creatinine level was included in the KDRI model [8], and the model reported by Irish et al. [5].

Elevated blood glucose levels potentially lead to renal microvascular formation, glomerular basement

---

**Table 6** The predictive value of prognosis models

|                        | ROC Area (95% CI) | Cut-Off Point | Sensitivity (%) | Specificity (%) |
|------------------------|-------------------|---------------|----------------|-----------------|
| **Discovery cohort**   |                   |               |                |                 |
| Donor Terminal Creatinine(mg/dL) | 0.753(0.622–0.883) | 1.3178 | 60.9% | 87.5% |
| Donor history of diabetes mellitus | 0.655(0.510–0.799) | 0.5 | 43.5% | 87.5% |
| CIT(h)                 | 0.706(0.573–0.839) | 11.25 | 43.5% | 91.7% |
| Donor IL-2(pg/mL)     | 0.714(0.585–0.843) | 66.415 | 95.7% | 45.8% |
| Prediction_system     | 0.894(0.798–0.955) | -0.896 | 86.96% | 85.42% |
| KDRI                  | 0.764(0.649–0.857) | 1.13 | 82.61% | 62.50% |
| DGF                   | 0.720(0.601–0.820) | 0.2767 | 69.57% | 66.67% |
| **Validation cohort** |                   |               |                |                 |
| Donor Terminal Creatinine(mg/dL) | 0.817(0.640–0.931) | 0.676 | 91.7% | 65% |
| Donor history of diabetes mellitus | 0.625(0.437–0.789) | 0 | 25% | 100% |
| CIT(h)                 | 0.769(0.586–0.899) | 8 | 83.33% | 65% |
| Donor IL-2(pg/mL)     | 0.819(0.643–0.932) | 87.11 | 100% | 55% |
| Prediction_system     | 0.879(0.715–0.967) | -0.984 | 0.8333 | 800 |
| KDRI                  | 0.829(0.655–0.938) | 0.8 | 100% | 60% |
| DGF                   | 0.667(0.479–0.823) | 0.327 | 66.7% | 80% |

*KDRI The Kidney Donor Risk Index, DGF, Delayed graft function score, CIT Cold ischemia time*

---

**Fig. 3** A nomogram predicting the risk of DGF in kidney transplant recipients
membrane thickening, mesangial dilation, nodular glomerulosclerosis and tubulointerstitial fibrosis, which are the main pathological changes associated with diabetic nephropathy, and diabetes is the most common cause of ESRD [24]. Studies have shown that diabetes is a risk factor for AKI, and kidney damage directly increases the risk of DGF after transplantation [25]. Multiple studies have identified links between diabetes and inflammatory markers, such as tumor necrosis factor-α, interleukin-6, and C-reactive protein [26–30]. These inflammatory markers are independent risk factors for DGF and are associated with kidney injury [31–33]. An animal study found that elevated glucose levels in diabetic mice cause persistent kidney damage during warm ischemia–reperfusion, and diabetic mice are more prone to DGF than nondiabetic mice [34]. In our study, the number of donors with a history of diabetes in the DGF group was greater than that in the IGF group. In the multivariate analysis, a donor history of diabetes was an independent risk factor for DGF.

CIT is an important factor affecting the recovery of renal graft function, and a CIT reaching 12 h will increase the probability of primary graft failure and vascular complications [35]. Most studies have found that CIT is a susceptibility factor for renal injury and is closely related to the occurrence of DGF [36–38]. Thus, a shorter CIT may reduce the incidence of DGF and improve graft outcomes. In this study, the mean CIT (10.61 ± 2.82) in the DGF group was approximately 12 h, which represented a significant difference compared with the mean CIT (8.36 ± 2.27) of the IGF group. In the multivariate analysis, CIT was an independent risk factor for DGF. During the management of high-risk organs, CIT should be minimized as much as possible, and the occurrence of DGF might be reduced by controlling CIT within 12 h.

Jesper et al. [39] used four predictive models reported by Irish et al. [40], Jeldres et al. [41], Chapal et al. [6], and Zaza et al. [7] to predict the occurrence of DGF, and the range of the C-statistic was 0.567–0.761, indicating that different parameter combinations might improve the predictive value of DGF in different populations. In 2009, the KDRI was proposed by Rao et al. for graft assessment and decision-making using donor factors. Although KDRI reflects graft and patient survival, its AUC for predicting the occurrence of DGF in this study was 0.764, which is limited because it only included a few clinical factors affecting prognosis. Chapal et al. [6] published a simple DGFS based on a multicenter and prospective cohort in France. It has a good predictive capacity (AUC at 0.73). By calculating the five explanatory variables of the model, a patient with DGFS < -0.50 was predicted to have no DGF, and the accuracy rate was 88%. In contrast, among patients with a DGFS > 1.2, half will experience a DGF. Therefore, this model is widely used and recommended for clinical practice.
used in Europe. In the present study, we found that donor terminal creatinine levels, a donor history of diabetes mellitus, CIT and donor IL-2 levels were related to the occurrence of DGF. The AUC, a measure of the diagnostic accuracy of risk factors for DGF, was 0.753, 0.655, 0.706 and 0.714 for donor terminal creatinine levels, a donor history of diabetes mellitus, CIT and donor IL-2 levels, respectively. We constructed a nomogram using these four independent risk factors to improve the accuracy of the prediction. The predictive ability of the model (AUC = 0.894) was better than that of the KDRI and DGFS.

Fig. 5 The calibration curve of the prediction system. A Calibration curve for internal validation using data from the discovery cohort. B The calibration curve for external validation using data from the validation cohort. C The calibration curve of the internally validated nomogram for the discovery cohort using the Brier score and R-squared values. D The calibration curve of the externally validated nomogram for the discovery cohort using the Brier score and R-squared values.
This study has several limitations. First, this study was performed at a single-center with a small sample size, and data from other centers have not been tested. Therefore, we hope that these findings will encourage external validation of the proposed model using data from more centers. In addition, this sample only covers Asian races, which has certain limitations in the process of promotion and application. Laboratory data are not dynamically observed and may cause bias. Finally, the scarce possibility of widespread use of the model due to the challenge represented by IL-2 determination in real life scenarios.

In summary, we constructed a DGF prediction model with high accuracy by including four factors (donor terminal creatinine levels, donor history of diabetes mellitus, CIT, and donor IL-2 levels) to provide clinicians with a useful tool that helps clinical decision-makers intervene more quickly and reduce the occurrence of DGF. IL-2 also participates in the kidney injury process and may be a potential marker of kidney injury.

Acknowledgements
Thanks to the nursing and medical team of the department of transplantation of the first affiliated hospital of Nanchang university

Authors’ contributions
ShiTao Zhao participated in the performance of the research design, data analysis and article writing. Yuan Liu and Chen Zhou participated in the performance of the research design and data analysis. Zide Chen, Zeyu Cai and JiaLiang Han participated in the performance of the research. JianSheng Xiao and Qi Xiao participated in research design, discussion, and article revision. All authors read and approved the final manuscript.

Funding
This study was supported by Natural Science Foundation of Jiangxi Province (no. 20212BAB206027, 20212BAG70017), Health Commission of Jiangxi Province (no.20203206).

Availability of data and materials
The datasets used and analyzed during the current study available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
The research was approved by the Ethics Committee of the First Affiliated Hospital of Nanchang University and written informed consent was obtained from each participant. All methods were performed according to the Declaration of Helsinki.
References

1. Tapiawala SN, Tinctam KJ, Cardella CJ, et al. Delayed graft function and the risk for death with a functioning graft. J Am Soc Nephrol. 2010;21(1):153–61.

2. Yarlagadda SG, Coga SG, Formica RN Jr, et al. Association between delayed graft function and allograft and patient survival: a systematic review and meta-analysis. Nephrol Dial Transplant. 2009;24(3):1039–47.

3. Ojo AO, Wolfe RA, Held PJ, et al. Delayed graft function: risk factors and implications for kidney allograft survival. Transplantation. 1997;63(7):968–74.

4. Yarlagadda SG, Coga SG, Garg AX, et al. Marked variation in the definition and diagnosis of delayed graft function: a systematic review. Nephrol Dial Transplant. 2008;23(9):2995–3003.

5. Irish WD, McCollum DA, Tesi RJ, et al. Nomogram for predicting the likelihood of delayed graft function in adult cadaveric kidney transplant recipients. J Am Soc Nephrol. 2003;14(11):2967–74.

6. Chapal M, Le Borgne F, Legendre C, et al. A useful scoring system for the prediction and management of delayed graft function following kidney transplantation from cadaveric donors. Kidney Int. 2014;86(6):1130–9.

7. Zaza G, Ferrari PM, Tessler G, et al. Predictive model for delayed graft function based on easily available pre-kidney transplant variables. Intern Emerg Med. 2015;10(2):135–41.

8. Rao PS, Schaubel DE, Guidinger MK, et al. A comprehensive risk quantification score for deceased donor kidneys: the donor kidney risk index. Transplantation. 2009;88(2):231–6.

9. Tammaro A, Kers J, Scamlebery AM, et al. Metabolic flexibility and innate immunity in kidney ischemia reperfusion injury: the fine balance between adaptive repair and tissue degeneration. Front Immunol. 2020;11:1346.

10. Rossana F, Alessandra S, Marco F, et al. Inflammaging and complement system: a link between acute kidney injury and chronic graft damage. Front Immunol. 2020;11:734.

11. Disha B, Zaid H, Asma D, et al. Delayed graft function in kidney transplantation. Curr Opin Organ Transplant. 2019;24:82–6.

12. Jiao B, Liu S, Liu H, et al. Hypothermic machine perfusion reduces delayed graft function and improves one-year graft survival of kidneys from expanded criteria donors: a meta-analysis. PLoS ONE. 2013;8(12): e81826.

13. Taniguchi T, Matsui H, Fujita T, et al. Structure and expression of a cloned cDNA for human interleukin-2. Nature. 1983;302(5906):305–10.

14. Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrow. Science. 1976;193(4257):1007–8.

15. Gaffen SL, Liu KD. Overview of interleukin-2 function, production and clinical applications. Cytokine. 2004;28(3):109–23.

16. Chinen T, Kannan AK, Levine AG, et al. An essential role for the IL-2 receptor in Treg cell function. Nat Immunol. 2016;17(11):1322–33.

17. Basile DP, Anderson MD, Stou TA. Pathophysiology of acute kidney injury. Compr Physiol. 2012;2(2):1303–53.

18. Zhang ZX, Wang S, Huang X, et al. NK cells induce apoptosis in tubular epithelial cells and contribute to kidney ischemia-reperfusion injury. J Immunol. 2008;181(1):7498–99.

19. Du C, Guan Q, Yin Z, et al. IL-2-mediated apoptosis of kidney tubular epithelial cells is regulated by the caspase-8 inhibitor c-FLIP. Kidney Int. 2005;67(4):1397–409.

20. Abbos AK, Trotta ER, Simeonov D. Revisiting IL-2: Biology and therapeutic prospects. Sci Immunol. 2018;3(25):eaat1482.

21. den Bakker E, Gemke RBJ, Bokenkamp A. Endogenous markers for kidney function in children: a review. Cnt Rev Clin Lab Sci. 2018;55(3):163–83.

22. George JA, Gounden V. Novel glomerular filtration markers. Adv Clin Chem. 2019;88:91–119.